Anagrelide influences thrombotic risk, and prolongs progression‐free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin

Autor:	Judit Demeter, Miklos Egyed, Zsófia Simon, Zoltán Gasztonyi, Árpád Illés, József Herczeg, Péter Dombi, Lajos Homor, Éva Karádi, Viktoria Gy Korom, Miklós Udvardy, Ibolya Ercsei, László Szerafin, Ádám Kellner
Rok vydání:	2020
Předmět:	medicine.medical_specialty Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Overall survival Humans Hydroxyurea Registries Myeloproliferative neoplasm Thrombotic risk Hungary Aspirin business.industry Extension study Disease progression Thrombosis Hematology General Medicine Anagrelide medicine.disease Treatment Outcome Health Care Surveys 030220 oncology & carcinogenesis Quinazolines Drug Therapy Combination business Thrombocythemia Essential 030215 immunology medicine.drug
Zdroj:	European Journal of Haematology. 105:408-418
ISSN:	1600-0609 0902-4441
DOI:	10.1111/ejh.13459
Popis:	We report an extension study of patients with essential thrombocythaemia (ET) in the Hungarian Myeloproliferative Neoplasm (HUMYPRON) Registry, which demonstrated that over 6 years anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous thrombotic events (TEs) vs hydroxyurea+aspirin.Data on patients with ET were collected through completion of a questionnaire developed according to 2008 WHO diagnostic criteria and with regard to Landolfi, Tefferi and IPSET criteria for thrombotic risk. Data were entered into the registry from 14 haematological centres. TEs, secondary malignancies, disease progression and survival were compared between patients with ET treated with anagrelide (n = 116) and with hydroxyurea+aspirin (n = 121).Patients were followed for (median) 10 years. A between-group difference in the number of patients with TEs was observed (25.9% anagrelide vs 38.0% hydroxyurea+aspirin; P = .052). Minor arterial events were more frequently reported in the hydroxyurea+aspirin group (P .001); there were marginally more reports of major arterial events in the anagrelide group (P = .049). TE prior to diagnosis was found to significantly influence TE incidence (P .001). Progression-free survival (P = .004) and survival (P = .001) were significantly increased for the anagrelide group vs hydroxyurea+aspirin.Anagrelide reduced TEs, and increased progression-free and overall survival vs hydroxyurea+aspirin over (median) 10 years.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c2402aac30de4b1d04a376bfccec932 https://doi.org/10.1111/ejh.13459 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.